STL Index for: Dupilumab

Prurigo Nodularis: Review and Emerging Treatments

Novel therapeutics are currently being explored for the treatment of Prurigo Nodularis. Nemolizumab and dupilumab both demonstrate promise in inhibiting specific central nervous system pathways responsible for transmission of the pruritic sensation.

Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis

Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.

Update on Drugs & Devices: September – October 2019

The latest drug & device update covers: Adalimumab-bwwd for SC injection (Hadlima™), Apremilast tablets (Otezla®), Calcipotriene + betamethasone dipropionate (Enstilar® foam Taclonex® topical suspension), Bempegaldesleukin + nivolumab for IV use (NKTR-214 + Opdivo®), Dupilumab for SC injection (Dupixent®), Magnetic muscle stimulation for body contouring (CoolTone™), Laser device for body contouring (eon™ FR).

Chronic Pruritus: A Review of Neurophysiology and Associated Immune Neuromodulatory Treatments

Chronic pruritus remains a difficult condition to treat with many non-specific therapeutic options. Recent scientific discoveries have elucidated the physiology associated with pruritus.

Skin Treatments Introduced in 2017

A look back at skin treatments introduced in 2017 for the following type/class of therapy: Antibiotic agents, anti-cancer agents, atopic dermatitis, dermal fillers, fabry disease, hereditary angioedema, herpes zoster, hidradenitis suppurativa, psoriasis, psoriatic arthritis, rosacea...

Dupilumab for Moderate-to-Severe Atopic Dermatitis

Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are limited due to toxicity and side effects. Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a promising therapeutic option.

Update on Drugs and Drug News: May-June 2017

Update on Dupilumab for SC injection Dupixent®, Dupilumab for SC injection, Avelumab for IV injection Bavencio®, Hyaluronic acidbased injectable dermal filler Juvéderm®, Biosimilar to adalimumab for SC injection Amgevita™ Vollure™ XC, Adalimumab for SC injection Humira®, and Amgevita™.

Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature

Standard therapies for atopic dermatitis have fallen short, prompting efforts to discover novel therapeutics for this disease. Dupilumab, a fully human monoclonal antibody that inhibits the actions of both IL-4 and IL-13, has shown promise.

Update on Drugs and Drug News: January-February 2015

Update on Apremilast tablets (Otezla®), Collagenase clostridium histolyticum for injection (Xiaflex®), Afamelanotide 16 mg subcutaneous bioresorbable implants (Scenesse®), Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Dupilumab SC injection, Apremilast tablets (Otezla®).

POPULAR